MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...
Business Insider1mon
Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions
Mediwound ( (MDWD)) has shared an announcement. Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment ...
ETF Daily News1mon
MediWound’s (MDWD) Buy Rating Reiterated at HC Wainwright
Shares of MediWound stock opened at $16.72 on Friday. The business has a 50-day simple moving average of $17.24 and a 200 day simple moving average of $17.66. MediWound has a one year low of $11. ...
Benzinga.com2mon
MediWound (NASDAQ:MDWD) Stock Quotes, Forecast and News Summary
Zacks Can MediWound Climb 57.49% to Reach the Level Wall Street Analysts Expect? MediWound (NASDAQ: MDWD) closed the last trading session at $18.89, gaining 21.4% over the past four weeks ...
news.stocktradersdaily5d
How the (MDWD) price action is used to our Advantage
Short MDWD slightly under 21.14, target 18.58, stop loss @ 21.2 Check the time stamp on this data. Updated AI-Generated Signals for Mediwound Ltd. (MDWD) available here: MDWD. Type a few symbols and ...
MediWound Ltd.: MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...